Shots:

• Akcea to receive $150M as option license fee with equal sharing with Ionis as equity investment in Akcea. Novartis to get exclusive WW development and commercialization rights for Akcea’s AKCEA-APO(a)-LRx (TQJ230) and will initiate P-III trial for cardiovascular outcomes
• In Jan-2107 Akcea and its subsidiary Ionis collaborated with Novartis to develop & commercialize AKCEA-APO(a)-LRx & AKCEA-APOCIII-LRx. for cardiovascular disorders
• AKCEA-APO(a)-LRx antisense drug developed using Ionis’ LIgand Conjugated Antisense- or LICA- technology- taregeted for inhibiting apolipoprotein(a)- or Apo(a) protein & established CVD and has been evaluated in P-II demonstrated reduction in Lp(a)- LDL-C- apoB- OxPL-apoB- OxPL-apo(a) levels  

Ref: Ionis Pharma | Image: MSN